Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Rev Med Suisse ; 20(864): 500-504, 2024 Mar 06.
Artículo en Francés | MEDLINE | ID: mdl-38445680

RESUMEN

The coronary artery calcium score (CAC-score) using imaging is a cardiovascular screening tool that can be used in adults with no known cardiovascular disease and no symptoms suggestive of a cardiovascular pathology. It involves calculating the amount of calcification in the coronary arteries on a low-dose, non-injected chest CT-scan. A positive score above 0 is associated with more cardiovascular events. The CAC-score is currently selectively recommended for certain adults at intermediate cardiovascular risk, when the introduction of lipid-lowering treatment or the intensification of preventive measures remain uncertain.


Le score calcique coronarien (CAC-score) utilisant l'imagerie est un outil de dépistage cardiovasculaire utilisable chez des adultes sans maladie cardiovasculaire connue et symptômes évoquant une pathologie cardiovasculaire. Il s'agit d'un calcul de la quantité de calcifications dans les artères coronaires lors d'un CT-scan thoracique non injecté à faible dose. Un score positif au-dessus de 0 est associé avec plus d'événements cardiovasculaires. Le CAC-score est actuellement recommandé sélectivement chez certains adultes à risque cardiovasculaire intermédiaire, lorsque l'introduction d'un traitement hypolipémiant ou l'intensification des mesures de prévention restent incertaines.


Asunto(s)
Enfermedades Cardiovasculares , Adulto , Humanos , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Calcio , Vasos Coronarios/diagnóstico por imagen , Factores de Riesgo , Factores de Riesgo de Enfermedad Cardiaca
2.
Prev Med ; 163: 107177, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35901973

RESUMEN

Smoking and depression are risk factors for acute coronary syndrome (ACS) that often co-exist. We investigated the evolution of depression according to smoking cessation one-year after ACS. Data from 1822 ACS patients of the Swiss multicenter SPUM-ACS cohort study were analyzed over a one-year follow-up. Participants were classified in three groups based on smoking status one-year post-ACS - continuous smokers, smokers who quit within the year, and non-smokers. Depression status at baseline and one-year was assessed with the Center for Epidemiologic Studies Depression scale (CES-D) and antidepressant drug use. A CES-D score ≥ 16 defined depression. A multivariate-adjusted logistic regression model was used to calculate odds ratios (OR) between groups. The study sample mean age was 62.4 years and females represented 20.8%. At baseline, 22.6% were depressed, 40.9% were smokers, and 47.5% of these quit smoking over the year post-ACS. In comparison to depressed continuous smokers, depressed smokers who quit had an adjusted OR 2.59 (95% confidence interval (CI) 1.27-5.25) of going below a CES-D score of 16 or not using antidepressants. New depression at one-year was found in 24.4% of non-depressed smokers who quit, and in 27.1% of non-depressed continuous smokers, with an adjusted OR 0.85 (95% CI 0.55-1.29) of moving to a CES-D score of ≥16 or using antidepressants. In conclusion, smokers with depression at time of ACS who quit smoking improved their depression more frequently compared to continuous smokers. The incidence of new depression among smokers who quit after ACS was similar compared to continuous smokers.


Asunto(s)
Síndrome Coronario Agudo , Cese del Hábito de Fumar , Síndrome Coronario Agudo/epidemiología , Estudios de Cohortes , Depresión/epidemiología , Femenino , Humanos , Persona de Mediana Edad , Fumar/efectos adversos , Fumar/epidemiología
3.
Circ Cardiovasc Qual Outcomes ; 17(8): e010790, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38899458

RESUMEN

BACKGROUND: Long-term control of cardiovascular risk factors after acute coronary syndrome (ACS) is the cornerstone for preventing recurrence. We investigated the extent of cardiovascular risk factor management in males and females with and without familial hypercholesterolemia (FH) 5 years after ACS. METHODS: We studied patients hospitalized for ACS between 2009 and 2017 in a Swiss multicenter prospective cohort study. FH was defined based on clinical criteria from the Dutch Lipid Clinic Network and Simon Broome definitions. Five years post-ACS, we assessed low-density lipoprotein-cholesterol (LDL-c) levels, lipid-lowering therapy (LLT), and other cardiovascular risk factors, comparing males to females with and without FH using generalized estimating equations. RESULTS: A total of 3139 patients were included; mean age was 61.4 years (SD, 12.1), 620 (19.8%) were female, and 747 (23.5%) had possible FH. Compared with males at 5-years post-ACS, females were more likely to not use statins (odds ratio, 1.61 [95% CI, 1.28-2.03]) and less likely to have combination LLT (odds ratio, 0.72 [95% CI, 0.55-0.93]), without difference between patients with FH and without FH. Females in both FH and non-FH groups less frequently reached LDL-c values ≤1.8 mmol/L (odds ratio, 0.78 [95% CI, 0.78-0.93]). Overall, patients with FH were more frequently on high-dose statins compared with patients without FH (51.0% versus 42.9%; P=0.001) and presented more frequently with a combination of 2 or more LLT compared with patients without FH (33.8% versus 17.7%; P<0.001), but less frequently reached LDL-c targets of ≤1.8 mmol/L (33.5% versus 44.3%; P<0.001) or ≤2.6 mmol/L (70.2% versus 78.1%; P=0.001). CONCLUSIONS: Five years after ACS, females had less intensive LLT and were less likely to reach target LDL-c levels than males, regardless of FH status. Males and females with FH had less optimal control of LDL-c despite more frequently taking high-dose statins or combination LLT compared with patients without FH. Long-term management of patients with ACS and FH, especially females, warrants optimization.


Asunto(s)
Síndrome Coronario Agudo , Biomarcadores , LDL-Colesterol , Factores de Riesgo de Enfermedad Cardiaca , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Hiperlipoproteinemia Tipo II , Humanos , Masculino , Femenino , Síndrome Coronario Agudo/diagnóstico , Síndrome Coronario Agudo/epidemiología , Síndrome Coronario Agudo/terapia , Síndrome Coronario Agudo/sangre , Persona de Mediana Edad , Hiperlipoproteinemia Tipo II/diagnóstico , Hiperlipoproteinemia Tipo II/sangre , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Hiperlipoproteinemia Tipo II/epidemiología , Hiperlipoproteinemia Tipo II/complicaciones , Factores Sexuales , Anciano , Factores de Tiempo , Estudios Prospectivos , Resultado del Tratamiento , LDL-Colesterol/sangre , Suiza/epidemiología , Medición de Riesgo , Biomarcadores/sangre , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Recurrencia , Disparidades en Atención de Salud , Prevención Secundaria , Disparidades en el Estado de Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA